Covered recipient · General Payments record
JORGE A GARCIA ZUAZAGA
Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$84,667.07
52 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,344.91 | 13 |
| Food and Beverage | $717.17 | 37 |
| Consulting Fee | $505.00 | 1 |
| Education | $99.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $83,420.09 | 18 |
| Ethicon Inc. | $505.00 | 1 |
| Lilly USA, LLC | $148.12 | 8 |
| Incyte Corporation | $104.57 | 4 |
| Janssen Biotech, Inc. | $99.99 | 1 |
| GENZYME CORPORATION | $92.64 | 4 |
| Amgen Inc. | $56.18 | 3 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $43.67 | 2 |
| LEO Pharma Inc. | $43.58 | 2 |
| Medimetriks Pharmaceuticals, Inc. | $38.49 | 2 |
| E.R. Squibb & Sons, L.L.C. | $35.05 | 2 |
| MAYNE PHARMA COMMERCIAL LLC | $24.66 | 2 |
| Regeneron Healthcare Solutions, Inc. | $22.16 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.84 | 1 |
| Sun Pharmaceutical Industries Inc. | $14.03 | 1 |
Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JORGE A GARCIA ZUAZAGA
NPI 1407979529 · CMS profile ID 830298
Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery
CONCORD TOWNSHIP, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
52 matching records · $84,667.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 52.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| LEO Pharma Inc. | $24.26 | 12/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053472505 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $18.84 | 12/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051613159 | CMS |
| Amgen Inc. | $13.96 | 12/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020607321 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 12/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016017329 | CMS |
| ABBVIE INC. | $617.00 | 12/05/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317463 | CMS |
| Regeneron Healthcare Solutions, Inc. | $22.16 | 12/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999181501 | CMS |
| Amgen Inc. | $20.00 | 11/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020607319 | CMS |
| LEO Pharma Inc. | $19.32 | 11/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053472499 | CMS |
| ABBVIE INC. | $106.40 | 11/09/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317461 | CMS |
| Lilly USA, LLC | $20.54 | 10/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031639745 | CMS |
| GENZYME CORPORATION | $17.75 | 10/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049910675 | CMS |
| ABBVIE INC. | $15.27 | 10/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317459 | CMS |
| Lilly USA, LLC | $19.36 | 10/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031612855 | CMS |
| Lilly USA, LLC | $16.14 | 10/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031684485 | CMS |
| ABBVIE INC. | $14,206.69 | 10/23/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317457 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $24.83 | 10/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051613157 | CMS |
| ABBVIE INC. | $16.73 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317455 | CMS |
| ABBVIE INC. | $282.50 | 10/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317453 | CMS |
| GENZYME CORPORATION | $20.00 | 10/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049910667 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 09/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016017257 | CMS |
| Medimetriks Pharmaceuticals, Inc. | $16.67 | 09/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987616463 | CMS |
| GENZYME CORPORATION | $18.89 | 09/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049910637 | CMS |
| ABBVIE INC. | $20.16 | 09/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317449 | CMS |
| ABBVIE INC. | $219.50 | 09/12/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317451 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $16.43 | 09/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060915859 | CMS |
| Lilly USA, LLC | $17.00 | 08/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031568653 | CMS |
| ABBVIE INC. | $14.80 | 08/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317447 | CMS |
| Incyte Corporation | $20.21 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044728399 | CMS |
| ABBVIE INC. | $16,267.49 | 07/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317445 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.84 | 07/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996559771 | CMS |
| ABBVIE INC. | $474.20 | 07/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317443 | CMS |
| Medimetriks Pharmaceuticals, Inc. | $21.82 | 07/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987616465 | CMS |
| ABBVIE INC. | $14.20 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317441 | CMS |
| Ethicon Inc. | $505.00 | 06/14/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 990874019 | CMS |
| Incyte Corporation | $23.96 | 06/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044728363 | CMS |
| ABBVIE INC. | $249.60 | 06/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317439 | CMS |
| Amgen Inc. | $22.22 | 05/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020607317 | CMS |
| Incyte Corporation | $40.33 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044728289 | CMS |
| Lilly USA, LLC | $17.67 | 05/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031612867 | CMS |
| Incyte Corporation | $20.07 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044728247 | CMS |
| Janssen Biotech, Inc. | $99.99 | 05/09/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988400963 | CMS |
| Lilly USA, LLC | $20.40 | 04/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031645287 | CMS |
| ABBVIE INC. | $16,278.97 | 04/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317437 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $8.23 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060915857 | CMS |
| ABBVIE INC. | $427.50 | 04/07/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317435 | CMS |
| ABBVIE INC. | $161.20 | 03/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317433 | CMS |
| Lilly USA, LLC | $16.99 | 02/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031612861 | CMS |
| Sun Pharmaceutical Industries Inc. | $14.03 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053877367 | CMS |
| Lilly USA, LLC | $20.02 | 02/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031645283 | CMS |
| ABBVIE INC. | $34,039.06 | 02/09/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997317431 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,893,327.58 | 407 |
| PY2024 | Principal investigator | $2,667,688.93 | 422 |
| PY2023 | Recipient | $18,196.50 | 3 |
| PY2023 | Principal investigator | $882,864.23 | 139 |
| PY2022 | Principal investigator | $164,380.88 | 32 |
| PY2021 | Recipient | $18,912.00 | 5 |
| PY2021 | Principal investigator | $12,300.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
407 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $37,500.00 | 12/26/2025 | Non-covered Recipient Entity Apex Clinical Research | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1235998993 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,541.00 | 12/25/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419159 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $37,500.00 | 12/24/2025 | Non-covered Recipient Entity Apex Dermatology And Skin Surgery Center, Llc | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1235998979 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202531796 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $491.50 | 12/22/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145945 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 12/19/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503240 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 12/19/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503244 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 12/19/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503247 |
| Principal investigator 1 | Incyte Corporation | $2,120.00 | 12/19/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503257 |
| Principal investigator 1 | Incyte Corporation | $2,309.00 | 12/19/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503264 |
| Principal investigator 1 | Incyte Corporation | $3,120.00 | 12/19/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503285 |
| Principal investigator 1 | Incyte Corporation | $824.50 | 12/17/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503299 |
| Principal investigator 1 | PFIZER INC. | $9,073.36 | 12/17/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228746591 |
| Principal investigator 1 | ABBVIE INC. | $2,297.00 | 12/16/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202530654 |
| Principal investigator 1 | PFIZER INC. | $514.56 | 12/16/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228736615 |
| Principal investigator 1 | PFIZER INC. | $6,606.23 | 12/16/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228748873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $877.00 | 12/15/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419081 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,530.00 | 12/15/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145949 |
| Principal investigator 1 | ABBVIE INC. | $1,167.55 | 12/11/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202530200 |
| Principal investigator 1 | PFIZER INC. | $11,000.48 | 12/11/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228749177 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $179,017.64 | 12/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289500 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $89,167.60 | 12/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289504 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $947.00 | 12/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289526 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $495.00 | 12/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289528 |
| Principal investigator 1 | ABBVIE INC. | $1,694.00 | 12/09/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202529748 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 12/08/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145930 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $679.00 | 12/08/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145934 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,812.50 | 12/08/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145938 |
| Principal investigator 1 | ABBVIE INC. | $32,376.58 | 12/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202528380 |
| Principal investigator 1 | ABBVIE INC. | $8,107.08 | 12/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202528432 |
| Principal investigator 1 | ABBVIE INC. | $6,498.72 | 12/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202528434 |
| Principal investigator 1 | ABBVIE INC. | $1,988.25 | 12/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202526302 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950.00 | 12/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288969 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,648.51 | 12/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289093 |
| Principal investigator 1 | ABBVIE INC. | $160.80 | 11/25/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202525368 |
| Principal investigator 1 | PFIZER INC. | $800.00 | 11/25/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228737142 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,321.90 | 11/24/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145941 |
| Principal investigator 1 | ABBVIE INC. | $506.25 | 11/20/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202525024 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202524511 |
| Principal investigator 1 | PFIZER INC. | $10,950.00 | 11/18/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228729226 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,011.00 | 11/17/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145919 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $616.00 | 11/17/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145922 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $821.00 | 11/17/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145925 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,035.93 | 11/14/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223288361 |
| Principal investigator 1 | PFIZER INC. | $2,660.18 | 11/13/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228724090 |
| Principal investigator 1 | ABBVIE INC. | $742.50 | 11/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523703 |
| Principal investigator 1 | ABBVIE INC. | $711.10 | 11/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523235 |
| Principal investigator 1 | ABBVIE INC. | $16,237.20 | 11/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202521639 |
| Principal investigator 1 | ABBVIE INC. | $33,661.64 | 11/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521657 |
| Principal investigator 1 | ABBVIE INC. | $4,509.78 | 11/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202523023 |
| Principal investigator 1 | Incyte Corporation | $108.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503222 |
| Principal investigator 1 | Incyte Corporation | $51.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503230 |
| Principal investigator 1 | Incyte Corporation | $162.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503234 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503250 |
| Principal investigator 1 | Incyte Corporation | $756.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503272 |
| Principal investigator 1 | Incyte Corporation | $1,950.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503289 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503293 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 11/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503296 |
| Principal investigator 1 | ABBVIE INC. | $4,036.08 | 11/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202520259 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 11/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228723816 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $99,130.61 | 11/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287873 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $297.00 | 11/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287917 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $275.00 | 11/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287921 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity Apex Dermatology And Skin Surgery Center, Llc | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235998981 |
| Principal investigator 1 | ABBVIE INC. | $726.30 | 10/29/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202519615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,783.00 | 10/24/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419097 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 10/22/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202518149 |
| Principal investigator 1 | Incyte Corporation | $108.00 | 10/22/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503226 |
| Principal investigator 1 | Incyte Corporation | $3,481.00 | 10/22/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503268 |
| Principal investigator 1 | Incyte Corporation | $57.00 | 10/22/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503276 |
| Principal investigator 1 | Incyte Corporation | $1,349.50 | 10/22/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503280 |
| Principal investigator 1 | Incyte Corporation | $2,425.00 | 10/22/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503305 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950.00 | 10/22/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287237 |
| Principal investigator 1 | ABBVIE INC. | $1,086.00 | 10/15/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202517011 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,400.00 | 10/15/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286985 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $441.50 | 10/14/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145910 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $593.00 | 10/14/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145914 |
| Principal investigator 1 | PFIZER INC. | $847.80 | 10/11/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228741765 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,692.00 | 10/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286695 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $385.00 | 10/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286697 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,564.00 | 10/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286699 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $715.00 | 10/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286701 |
| Principal investigator 1 | ABBVIE INC. | $3,631.24 | 10/09/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202515971 |
| Principal investigator 1 | ABBVIE INC. | $23,544.71 | 10/09/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,304.00 | 10/09/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419092 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 10/08/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261008 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 10/08/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261226 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 10/08/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261251 |
| Principal investigator 1 | Janssen Research & Development, LLC | $800.00 | 10/08/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261650 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $322,777.32 | 10/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER, LLC | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190312931 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 10/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223286555 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950.00 | 10/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223286559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $832.00 | 10/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419143 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,034.90 | 10/06/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,131.97 | 10/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286111 |
| Principal investigator 1 | ABBVIE INC. | $1,350.65 | 09/30/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202512790 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,596.00 | 09/29/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419119 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $594.00 | 09/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285927 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 09/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285929 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $165.00 | 09/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285931 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,346.00 | 09/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285933 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $55.00 | 09/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285935 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,764.60 | 09/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 09/25/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261170 |
| Principal investigator 1 | PFIZER INC. | $6,660.20 | 09/24/2025 | Non-covered Recipient Entity Jorge GarciaZuazaga | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228750766 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $550.00 | 09/24/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285864 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,031.50 | 09/22/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145897 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,515.00 | 09/22/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145902 |
| Principal investigator 1 | ABBVIE INC. | $8,725.00 | 09/18/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202511312 |
| Principal investigator 1 | ABBVIE INC. | $430.14 | 09/16/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202510990 |
| Principal investigator 1 | ABBVIE INC. | $742.50 | 09/15/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202510898 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $187.60 | 09/12/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285359 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,000.00 | 09/12/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285361 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 09/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202510396 |
| Principal investigator 1 | PFIZER INC. | $32,119.91 | 09/09/2025 | Non-covered Recipient Entity Jorge GarciaZuazaga | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228758427 |
| Principal investigator 1 | ABBVIE INC. | $1,056.37 | 09/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202510222 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,283.00 | 09/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419150 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 09/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503210 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 09/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503214 |
| Principal investigator 1 | Incyte Corporation | $28,000.00 | 09/05/2025 | Non-covered Recipient Entity APEX DERMATOLOGY MAYFIELD HEIGHTS | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240503218 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $891.00 | 09/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285149 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $297.00 | 09/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285151 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $165.00 | 09/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285153 |
| Principal investigator 1 | ABBVIE INC. | $24,950.00 | 09/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202508464 |
| Principal investigator 1 | ABBVIE INC. | $6,383.94 | 09/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202508554 |
| Principal investigator 1 | ABBVIE INC. | $27,392.63 | 09/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202508652 |
| Principal investigator 1 | PFIZER INC. | $1,686.16 | 09/03/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228758943 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $400.00 | 09/03/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145887 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,163.50 | 09/03/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145894 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,589.42 | 09/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284895 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $250.00 | 09/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284997 |
| Principal investigator 1 | ABBVIE INC. | $1,844.00 | 09/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202506905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $330.00 | 09/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284755 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 09/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284757 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 09/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284759 |
| Principal investigator 1 | ABBVIE INC. | $742.50 | 08/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505975 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 08/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284653 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $441.50 | 08/25/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145890 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $30,126.63 | 08/22/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284525 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950.00 | 08/22/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284551 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,400.00 | 08/20/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284435 |
| Principal investigator 1 | ABBVIE INC. | $2,780.00 | 08/19/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505071 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,715.00 | 08/18/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145871 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,593.00 | 08/18/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145876 |
| Principal investigator 1 | ABBVIE INC. | $1,923.75 | 08/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202504355 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950.00 | 08/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284169 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 08/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284171 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 08/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284173 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $220.00 | 08/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284175 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 08/12/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202504225 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,828.38 | 08/11/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145882 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,579.00 | 08/08/2025 | Non-covered Recipient Entity Apex Clinical Research Center, Llc | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235998983 |
| Principal investigator 1 | ABBVIE INC. | $3,637.10 | 08/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202502480 |
| Principal investigator 1 | ABBVIE INC. | $58,581.47 | 08/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202502482 |
| Principal investigator 1 | ABBVIE INC. | $3,510.80 | 08/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202501392 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,163.00 | 08/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145862 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 08/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145867 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,159.04 | 08/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283379 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,986.80 | 08/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283381 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $330.00 | 08/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283583 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,861.36 | 08/01/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283617 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,078.00 | 07/31/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419132 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 07/24/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202499566 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 07/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283030 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 07/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283032 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,617.65 | 07/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283040 |
| Principal investigator 1 | ABBVIE INC. | $160.80 | 07/17/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498608 |
| Principal investigator 1 | ABBVIE INC. | $381.90 | 07/17/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202498612 |
| Principal investigator 1 | ABBVIE INC. | $144.68 | 07/17/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202498614 |
| Principal investigator 1 | ABBVIE INC. | $520.00 | 07/17/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202498616 |
| Principal investigator 1 | ABBVIE INC. | $1,996.50 | 07/17/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202498652 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,843.00 | 07/14/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145850 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,761.00 | 07/14/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145856 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,822.00 | 07/11/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419105 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 07/11/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228773672 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,135.00 | 07/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419086 |
| Principal investigator 1 | Janssen Research & Development, LLC | $652.00 | 07/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419128 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,661.00 | 07/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419154 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,828.38 | 07/07/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145858 |
| Principal investigator 1 | ABBVIE INC. | $12,896.68 | 07/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202495123 |
| Principal investigator 1 | ABBVIE INC. | $33,519.60 | 07/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495125 |
| Principal investigator 1 | ABBVIE INC. | $1,378.86 | 07/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202495183 |
| Principal investigator 1 | ABBVIE INC. | $2,292.50 | 07/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495185 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,565.70 | 07/02/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145852 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,103.74 | 07/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282204 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,526.00 | 06/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419113 |
| Principal investigator 1 | ABBVIE INC. | $2,250.00 | 06/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202493265 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $275.00 | 06/25/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $814.00 | 06/24/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261284 |
| Principal investigator 1 | Janssen Research & Development, LLC | $832.00 | 06/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419138 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,363.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260984 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261020 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261275 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261306 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 06/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261719 |
| Principal investigator 1 | ABBVIE INC. | $1,336.50 | 06/18/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202492241 |
| Principal investigator 1 | ABBVIE INC. | $1,925.90 | 06/17/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202491831 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $492.00 | 06/16/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145844 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 06/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223281230 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,150.00 | 06/10/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 06/10/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261556 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,000.00 | 06/09/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175419123 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,597.18 | 06/09/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145841 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60,530.51 | 06/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280944 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261013 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261162 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,363.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261341 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261520 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261527 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261539 |
| Principal investigator 1 | Janssen Research & Development, LLC | $824.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261661 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 06/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261686 |
| Principal investigator 1 | ABBVIE INC. | $8,000.00 | 06/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489021 |
| Principal investigator 1 | ABBVIE INC. | $2,036.80 | 06/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202489023 |
| Principal investigator 1 | ABBVIE INC. | $17,027.54 | 06/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489027 |
| Principal investigator 1 | ABBVIE INC. | $1,762.94 | 06/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202489079 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 06/02/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261107 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 06/02/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261260 |
| Principal investigator 1 | PFIZER INC. | $2,695.00 | 05/30/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228773358 |
| Principal investigator 1 | ABBVIE INC. | $390.00 | 05/29/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202486807 |
| Principal investigator 1 | PFIZER INC. | $4,300.00 | 05/29/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228771358 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $32,000.00 | 05/28/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280458 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $32,910.00 | 05/28/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280460 |
| Principal investigator 1 | ABBVIE INC. | $1,480.00 | 05/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202486163 |
| Principal investigator 1 | ABBVIE INC. | $285.42 | 05/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202486165 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $258.00 | 05/27/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145835 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,427.60 | 05/27/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145838 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,654.71 | 05/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280300 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 05/21/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261403 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,654.68 | 05/19/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145847 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,845.00 | 05/15/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261060 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,828.38 | 05/12/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145832 |
| Principal investigator 1 | ABBVIE INC. | $1,459.40 | 05/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202484239 |
| Principal investigator 1 | ABBVIE INC. | $5,779.26 | 05/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202482517 |
| Principal investigator 1 | ABBVIE INC. | $17,474.16 | 05/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482543 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950.00 | 05/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279114 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 05/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279116 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,831.05 | 05/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279134 |
| Principal investigator 1 | ABBVIE INC. | $2,018.04 | 05/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202481265 |
| Principal investigator 1 | PFIZER INC. | $9,831.22 | 05/06/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228723066 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $275.00 | 05/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260945 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,845.00 | 04/28/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261000 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261322 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261469 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261485 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261514 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261590 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $36,000.00 | 04/28/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145819 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,123.18 | 04/28/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145823 |
| Principal investigator 1 | Eli Lilly and Company | $5,000.00 | 04/25/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | No dispute reported | 06/30/2026 | 1187874995 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $330.00 | 04/25/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278636 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 04/24/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202479186 |
| Principal investigator 1 | Amgen Inc. | $6,445.00 | 04/24/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246639159 |
| Principal investigator 1 | ABBVIE INC. | $10,500.00 | 04/22/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202478325 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,081.00 | 04/14/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145815 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,475.00 | 04/11/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277942 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 04/11/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277944 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,970.56 | 04/11/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278040 |
| Principal investigator 1 | ABBVIE INC. | $1,393.20 | 04/10/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202475828 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $45,597.84 | 04/09/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235998985 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 04/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202474966 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 04/08/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228778521 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,393.00 | 04/07/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145765 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,133.58 | 04/07/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145772 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,632.38 | 04/07/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145774 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $665.00 | 04/07/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145794 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 04/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo | No dispute reported | 06/30/2026 | 1240503198 |
| Principal investigator 1 | Incyte Corporation | $630.00 | 04/04/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo | No dispute reported | 06/30/2026 | 1240503202 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260867 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260874 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260906 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260938 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261066 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261082 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261131 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261196 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261202 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261268 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261333 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261357 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261428 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261461 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261476 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261498 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261506 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261613 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261629 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261703 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 04/04/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261711 |
| Principal investigator 1 | ABBVIE INC. | $10,000.00 | 04/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202472101 |
| Principal investigator 1 | ABBVIE INC. | $14,739.18 | 04/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202472104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 04/02/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $824.00 | 04/02/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261123 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,700.00 | 04/02/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145761 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $115.00 | 04/02/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145809 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,064.06 | 04/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277492 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 03/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260915 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 03/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260993 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 03/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261213 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 03/28/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261378 |
| Principal investigator 1 | Amgen Inc. | $1,500.00 | 03/25/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | No dispute reported | 06/30/2026 | 1246639151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 03/24/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260890 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 03/24/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261299 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $50.00 | 03/24/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145777 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,184.90 | 03/24/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145788 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,074.00 | 03/21/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $824.00 | 03/20/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 03/19/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260961 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 03/19/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/19/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261348 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,363.00 | 03/19/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 03/19/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261421 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,363.00 | 03/19/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261669 |
| Principal investigator 1 | ABBVIE INC. | $3,250.00 | 03/11/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202462407 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,200.00 | 03/10/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145741 |
| Principal investigator 1 | ABBVIE INC. | $3,771.10 | 03/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202461011 |
| Principal investigator 1 | ABBVIE INC. | $24,950.00 | 03/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202461136 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,686.40 | 03/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276133 |
| Principal investigator 1 | ABBVIE INC. | $5,118.80 | 03/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202457931 |
| Principal investigator 1 | ABBVIE INC. | $4,215.71 | 03/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202455844 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,044.50 | 03/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145728 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,968.00 | 03/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145782 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,000.00 | 03/03/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226145828 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,929.20 | 03/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260882 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,878.68 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261242 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261492 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,878.68 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261567 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,878.68 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261605 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 02/27/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261634 |
| Principal investigator 1 | PFIZER INC. | $7,300.00 | 02/26/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228750295 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $36,566.96 | 02/26/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275653 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,092.00 | 02/24/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145786 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 02/21/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260852 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $45,610.57 | 02/19/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275391 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,000.00 | 02/18/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145731 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,828.38 | 02/18/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145736 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,200.00 | 02/18/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145757 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 02/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M19-977 - A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 1202451336 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 02/13/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202451340 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,000.00 | 02/10/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145805 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,238.55 | 02/10/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145812 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 02/07/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274985 |
| Principal investigator 1 | ABBVIE INC. | $11,598.38 | 02/06/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202448660 |
| Principal investigator 1 | PFIZER INC. | $3,954.72 | 02/05/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228751631 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274869 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $165.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274871 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $165.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274873 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274875 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $220.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274877 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $975.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274879 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $525.00 | 02/05/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274881 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,812.20 | 02/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145724 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $676.00 | 02/04/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145753 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 02/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175260953 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,095.40 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,660.68 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261045 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261099 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,878.68 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261115 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,234.40 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261220 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,878.68 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261451 |
| Principal investigator 1 | Janssen Research & Development, LLC | $824.00 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 01/29/2025 | Non-covered Recipient Entity Apex Clinic Rsrch Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175261574 |
| Principal investigator 1 | Amgen Inc. | $190,550.93 | 01/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639155 |
| Principal investigator 1 | Amgen Inc. | $115,373.97 | 01/27/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) | No dispute reported | 06/30/2026 | 1246639157 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $305.68 | 01/27/2025 | Non-covered Recipient Entity Apex Clinical Research | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235998991 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,471.58 | 01/27/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145744 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 01/23/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo | No dispute reported | 06/30/2026 | 1240503205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,200.00 | 01/21/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226145748 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $46,209.50 | 01/16/2025 | Non-covered Recipient Entity Apex Clinical Research Center | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235998987 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,265.00 | 01/16/2025 | Non-covered Recipient Entity Apex Derm Mayfield Hts | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175261744 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,799.60 | 01/13/2025 | Non-covered Recipient Entity Apex Clinical Research Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145800 |
| Principal investigator 1 | Eli Lilly and Company | $790,405.65 | 01/08/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187876213 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $98.55 | 01/08/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273807 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $130,278.06 | 01/03/2025 | Non-covered Recipient Entity Apex Clinical Research Center | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235998989 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,139.15 | 01/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273551 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $26.80 | 01/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273553 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,189.25 | 01/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273555 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $55.00 | 01/03/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223273557 |
| Principal investigator 1 | ABBVIE INC. | $2,018.04 | 01/02/2025 | Non-covered Recipient Entity APEX CLINICAL RESEARCH CENTER LLC | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202435066 |